Supplementary Tables S1-S24 from Integrative Analysis of a Large Real-World Cohort of Small Cell Lung Cancer Identifies Distinct Genetic Subtypes and Insights into Histologic Transformation

Supplementary Table S1: First-, second-, and third-line systemic therapy in the SCLC clinical cohort.
Supplementary Table S2: Genes analyzed as part of this study.
Supplementary Table S3: Prevalence of alterations in the genes analyzed.
Supplementary Table S4: Prevalence of gene alterations in 81 cases with liquid biopsies.
Supplementary Table S5: Chromosomal losses and gains in SCLC.
Supplementary Table S6: TET2 loss of function alterations detected in SCLCs.
Supplementary Table S7: Manual review of specific mutation subgroups in SCLCs.
Supplementary Table S8: Patterns of gene alterations in SMARCA4 altered and wild-type tumors.
Supplementary Table S9: Prevalence of gene alterations in rearrangement-positive SCLCs.
Supplementary Table S10: Univariate analysis of association between gene alterations and overall surival in the clinical cohort of stage III/IV SCLC tumors.
Supplementary Table S11: Patterns of tumor mutational burden based on site of biopsy.
Supplementary Table 12: Summary of tumor purity and tumor mutational burden by biopsy site.
Supplementary Table S13: Aneuploidy patterns based on site of biopsy.
Supplementary Table S14: Comparison of gene alterations in each biopsy site against lung biopsies.
Supplementary Table S15: Comparison of gene alterations in liver and brain metastases.
Supplementary Table S16: Summary of PTEN alterations in brain and other biopsy sites.
Supplementary Table S17: Patterns of co-occurrence and mutual exclusivity between gene alterations in the overall SCLC cohort.
Supplementary Table S18: Patterns of gene alterations in TP53 and/or RB1 mutant and wild-type cohorts.
Supplementary Table S19: Patterns of gene alterations in young and older patients with SCLC.
Supplementary Table S20: Patterns of gene alterations in HPV positive and HPV negative tumors.
Supplementary Table S21: Manual review of specific HPV+ SCLCs.
Supplementary Table S22: Patterns of gene alterations in STK11 mutant and wild-type cohorts.
Supplementary Table S23: Patterns of gene alterations in EGFR mutant and wild-type cohorts.
Supplementary Table S24: EGFR kinase domain alterations identified in the overall SCLC cohort.

补充表 S1：小细胞肺癌临床队列中的第一线、第二线和第三线系统性治疗。
补充表 S2：作为本研究一部分分析的基因。
补充表 S3：分析基因中变异的普遍性。
补充表 S4：81 例液体活检中基因变异的普遍性。
补充表 S5：小细胞肺癌中的染色体丢失和获得。
补充表 S6：在小细胞肺癌中检测到的 TET2 功能丧失变异。
补充表 S7：对小细胞肺癌中特定突变亚组的手动审查。
补充表 S8：SMARCA4 突变和野生型肿瘤中基因变异的模式。
补充表 S9：重排阳性小细胞肺癌中基因变异的普遍性。
补充表 S10：在 III/IV 期小细胞肺癌肿瘤的临床队列中，基因变异与总生存率之间关联的单因素分析。
补充表 S11：基于活检部位的肿瘤突变负荷模式。
补充表 S12：按活检部位总结的肿瘤纯度和肿瘤突变负荷。
补充表 S13：基于活检部位的非整倍体模式。
补充表 S14：各活检部位基因变异与肺活检的对比。
补充表 S15：肝脏和脑转移中基因变异的对比。
补充表 S16：大脑及其他活检部位 PTEN 突变的总结。
补充表 S17：整体小细胞肺癌队列中基因变异共现和互斥的模式。
补充表 S18：TP53 和/或 RB1 突变及野生型队列中基因变异的模式。
补充表 S19：小细胞肺癌年轻和老年患者中基因变异的模式。
补充表 S20：HPV 阳性和 HPV 阴性肿瘤中基因变异的模式。
补充表 S21：特定 HPV+ 小细胞肺癌的手动审查。
补充表 S22：STK11 突变和野生型队列中基因变异的模式。
补充表 S23：EGFR 突变和野生型队列中基因变异的模式。
补充表 S24：在整体小细胞肺癌队列中确定的 EGFR 酪氨酸激酶结构域变异。